Dear Sir,We welcome that a case-control study to explore associations between use of menopausal hormone therapy (MHT) and risk of breast cancer has been performed in Germany. 1 However, we are concerned by several shortcomings of this study. We cannot find an explanation or hypothesis, respectively, why 44.0% of randomly selected controls did not participate and a further 12.6% controls did not respond. These are relatively substantial numbers, compared to many other comparable case-controls studies of the studied context. 2,3 It is difficult to understand the nature of both varying and steadily decreasing absolute numbers of study women used for analyses. For example, overall there were 3,464 eligible cases for analyses (Table I) 1 , but how does this correspond to the sum of 4,359 cases (in situ disease excluded) in Figure 1 1 , reflecting absolute and relative numbers of study women with reported ever, current and past use, respectively? Likewise, the numbers of controls do not match.Unfortunately, the authors do not report how they utilized the wealth of data probably accumulated, using a memory aid to recall MHT histories apparently dating back for decades in study women. For example, how did the authors handle the histories of women reporting, i.e., cyclical and continuous combined MHT, respectively, or different preparations containing different estrogenic and progestogenic compounds? We know that long-term use of MHT in German has been both common, at least until recently, and often comprising changes in preparations. [4][5][6][7] We doubt that analyses restricted to the most recent therapy modalities render valid assumptions about risk and support inferences about differences in risks regarding both differences among regimens and the impact on histological subtypes.Finally, we are concerned that women who were premenopausal and women under 55 years of age, whose menopausal status was unclear because of hysterectomy or MHT, were excluded from the reported analyses. Women with ''unclear'' status also encounter risks of breasts cancer. Given the fact that substantial numbers of German women start MHT already before the age of 50 6-8 and that hysterectomy rates were calculated to be 25% in women aged 40-69 years in West German, 7 one would have liked to see more details on risk of breast cancer in these subgroups of women in the two study regions. 1